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Background: Although several trials have demonstrated the safety of drug-eluting
stent (DES) implantation for acute myocardial infarction (AMI) patients, care must be
exercised when DES are implanted in AMI cases because of the risk of in-stent throm-
bosis or adverse side effects of antiplatelet agents. On the other hand, recently,
there has beenmuch improvement in bare metal stents (BMSs), and thus, the efﬁcacy
of BMS implantation should be reevaluated.
Methods: We investigated the primary and long-term outcome of BMS implantation
for AMI patients in the DES era (July 2004 to December 2006; n = 97 [Group 1]) and
compared the results with those in the pre-DES era (January 2002 to June 2004;
n = 81 [Group 2]), retrospectively.
Results: The most frequently used BMS in Group 1 was the Driver stent (63.9%) and in
Group 2 the Duraﬂex stent (44.4%). Stent length and diameter were not signiﬁcantly
different between Group 1 and Group 2. The rates of in-stent restenosis, and target
lesion revascularization were lower in Group 1 than in Group 2. Restenosis frequently
occurred in small vessel lesions and in lesions that had required more than 10 atm
fully to dilate the pre-dilatation balloon at the primary PCI.
Conclusions: Currently available BMSs are much more effective than old-type BMSs.
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standard deviation (S.D.) and the categorical data
as frequencies (percentages). Continuous variables
were compared using the unpaired t-test. Binary190
Background
Many studies have shown that primary percuta-
neous coronary intervention (PCI) is an effective
treatment for acute myocardial infarction (AMI)
patients [1—5]. Especially, primary stent implanta-
tion for AMI patients improves the reperfusion rate
and decreases cardiovascular events and restenosis
rates following percutaneous coronary intervention
[6—8]. The restenosis rates of old-type bare metal
stents (BMSs) such as Palmatz-Schatz, Wiktor, and
Gianturco-Rubin were reported 17—25%, respec-
tively [9,10]. Today, drug-eluting stents (DESs) are
widely used. DESs have reduced the rates of in-stent
restenosis (ISR) and target lesion revasculariza-
tion (TLR) compared with BMSs [11,12], Recently,
two randomized studies of the safety and efﬁ-
cacy of DES implantation for AMI patients were
published [13,14]. In one study, sirolimus-eluting
stents were more efﬁcacious than BMSs in reducing
the rates of restenosis and target-vessel revas-
cularization. In the other study, taxolimus-eluting
stents were not superior to BMSs for reduction of
target lesion revascularization and major cardiac
events. However, while the two studies showed
similarities in the results obtained with DESs (TLR
rates were 5.6% and 5.3%, respectively), the results
obtained for BMSs were different (TLR rates were
13.4% and 7.8%, respectively), thereby affecting
the conclusions of each study. Thus it may be of
value to reevaluate the efﬁcacy of recent BMS
implantation for AMI patients. Several studies have
suggested that the mechanism of ISR after BMS
implantation for AMI patients is different from
that of patients with stable angina pectoris (AP)
[13,14]. Therefore DES may not be as beneﬁ-
cial for AMI patients as for stable AP patients.
In addition, care should be exercised for DES
implantation in AMI patients because of the risk
of acute, subacute, and late thrombosis after DES
implantation or adverse side effects of antiplatelet
agents.
In this study, we investigated the primary and
long-term outcome of BMS implantation for AMI
patients in the DES era by comparing the results
with those in the pre-DES era, retrospectively.
MethodsSubjects
From July 2004 to December 2006, 99 patients
underwent PCI in our hospital. BMSs were implanted
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erm outcomes of these 97 patients (Group 1)
ere compared with the results of 81 sequen-
ial AMI patients who underwent primary PCI (BMS
mplantation) from January 2002 to June 2004
Group 2).
rimary end point
he primary end point was a composite of major
dverse cardiac and cerebrovascular events (death
rom cardiac causes, myocardial infarction, and
schemia-driven TLR) within the ﬁrst 12 months of
ollow-up. TLR was deﬁned as revascularization for
stenosis within the stented region or within 5mm
f the distal or proximal edges of the stent.
Successful stenting was deﬁned as a ﬁnal steno-
is of less than 50% of the vessel diameter after
mplantation of the study stent. Treatment success
as deﬁned as a ﬁnal stenosis of less than 50% of
he vessel diameter after any percutaneous inter-
ention.
uantitative coronary angiography
oronary angiograms were digitally recorded at
aseline, post procedure, and at follow-up with
n automated edge-detection system (CAAS II,
ie Medical Imaging). The single projection in
hich a stenosis appeared to be most severe was
sed. A contrast-ﬁlled nontapered catheter tip
as used for calibration and reference diame-
er was determined by interpolation. Quantitative
easurements included the diameter of the ref-
rence vessel, the minimal luminal diameter,
nd the extent of diametric stenosis deﬁned as
(reference vessel diameter−minimal lumen diam-
ter)/reference vessel diameter]× 100. We deﬁned
SR as stenosis of at least 50% of the minimal lumi-
al diameter in the stented area and within the
argins 5mm proximal and distal to each stent
dge.
tatistical analysis
uantitative data are presented as mean±ariables were compared by means of the Fisher
xact test. Statistical signiﬁcance was deﬁned as
value of less than 0.05. All statistical analyses
ere performed using JMP 5 software (SAS Insti-
ute, Cary, NC, USA).
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Table 1 Baseline patient characteristics
Group 2: pre-DES era January
2002—June 2004 (n = 81)
Group 1: DES era July
2004—December 2006 (n = 97)
p
Age (year) 66.7± 9.9 66.8± 9.2 0.78
Male, n (%) 71 (87.7) 79 (81.4) 0.26
Hypertension, n (%) 45 (55.6) 57 (58.8) 0.67
Hyperlipidemia, n (%) 51 (63.0) 58 (59.8) 0.67
Diabetes mellitus, n (%) 38 (46.9) 41 (42.3) 0.54
Smoking, n (%) 51 (63.0) 67 (69.1) 0.39
Hyperuricemia, n (%) 11 (13.6) 14 (10.3) 0.87
Hemodialysis, n (%) 5 (6.2) 7 (7.2) 0.78
































































gStatin, n (%) 38 (46.9)
a The percentage of the patients who had been taking or s
as angiotensin converting enzyme inhibitor (ACE-I) or angioten
esults
aseline and procedural characteristics
aseline characteristics of the enrolled patients are
hown in Table 1. The percentage of the patients
ho had been taking or started to take statin
r rennin—angiotensin system inhibitors such as
ngiotensin converting enzyme inhibitor (ACE-I) or
ngiotensin receptor blocker (ARB) was statistically
igniﬁcantly higher in Group 1 than in Group 2.
ther baseline patient characteristics were not sig-
iﬁcantly different between Group 1 and Group 2.
Lesion characteristics and procedural character-
stics are shown in Table 2. Lesion characteristics
ere not signiﬁcantly different between Group 1
nd Group 2. The most frequently used BMS in
roup 1 was the Driver stent (63.9%) and in Group
it was Duraﬂex (44.4%) (Fig. 1). Stent length and
iameter were not signiﬁcantly different between
n Group 1 and in Group 2.
linical outcome
linical outcomes are shown in Table 3. The ratio of
ajor adverse cerebral and cardiac events except
LR rate was not signiﬁcantly different between
roup 1 and Group 2. TLR rate was signiﬁcantly
ower in Group 1 than in Group 2 (5.1% in Group
vs. 16.0% in Group 2, p = 0.016).
ngiographic analysis
mong the 178 enrolled patients, 123 patients
68 in Group 1 and 55 in Group 2) underwent
ollow-up CAG. Quantitative coronary angiogra-
hy (QCA) ﬁndings of the 123 patients are shown
n Table 4. Although reference diameter, mini-






d to take statin or rennin—angiotensin system inhibitors such
ceptor blocker (ARB).
tenosis before and after PCI were not signiﬁcantly
ifferent between Group 1 and Group 2, MLD,
ercent diametric stenosis, late loss and binary
estenosis rate in- and distal-portion of the stents
ere signiﬁcantly lower in Group 1 than in Group 2.
haracteristics of restenotic lesions
mong the 68 patients who underwent follow-up
AG in Group 1, in-stent restenosis occurred in 5
ases. Stent diameter was smaller in the restenosis
roup than non-restenosis group (Table 5). For the
of the 5 restenosis lesions, high pressure (more
han 10 atm) was needed to fully dilate the pre-
ilatation balloon at the primary PCI. That is, it was
uspected that AMI occurred by the formation of
hrombus in the chronic severe stenotic lesions. The
est of the restenosis lesion was small vessel lesion
ith a diameter of 2.13mm of vessel diameter.
iscussion
he major ﬁnding of this study was that implan-
ation of currently available BMSs in AMI patient
rovides better outcome than old-type BMSs and
he results are comparable to those of DESs. This
mprovement in outcome of the currently available
MSs may be due to several reasons. First, improve-
ents in the material and structural design of the
MS may have contributed to the better results.
n our study, the Driver stent was most frequently
sed in the DES era. There are several reports sug-
esting that the long-term outcome of the Driver
tent is better than the outcome achieved with the
ld-type BMS [15,16], because of the better struc-
ure and material of the Driver stent. Next, the
ide use of renin—angiotensin system inhibitors and
tatins in recent years may be related to the bet-
192 H. Fujimoto et al.
Table 2 Lesion and procedure characteristics
Group 2: pre-DES era January
2002—June 2004 (n = 81)
Group 1: DES era July
2004—December 2006 (n = 97)
p
LAD, n (%) 28 (34.6) 33 (34.0) 0.94
LCX, n (%) 15 (18.5) 17 (17.5) 0.86
RCA, n (%) 36 (44.4) 45 (46.4) 0.80
LMT, n (%) 2 (2.5) 2 (2.1) 0.86
Stent length (mm) 20.3± 3.3 21.0± 5.8 0.65
Stent diameter (mm) 3.02± 0.41 3.12± 0.43 0.58
Number of stents 1.02± 0.16 1.03± 0.17 0.80






tFigure 1 Types o
ter results of recent AMI treatment. Several small
sized studies suggest that ACE-Is and ARBs have
anti-inﬂammatory effects, and may reduce the rate
of ISR [17,18]. Recently, statins have been more
widely used than before, based on the guideline
that recommends rigid control of the plasma LDL
cholesterol level to reduce major adverse cardiac




Table 3 Clinical outcome
Group 2: pre-DES era J
2002—June 2004 (n = 81
Acute or late thrombosis, n (%) 1 (1.2)
Cardiac death, n (%) 3 (3.6)
Myocardial infarction, n (%) 1 (1.2)
Cerebrovascular events, n (%) 0 (0.0)
TLR, n (%) 13 (16.0)
In-hospital death, n (%) 2 (2.5)
Follow-up length (months) 11.7± 2.1
TLR, target lesion revascularization.re metal stents.
ffects, which may suppress neointima formation
20,21]. Although there is no solid evidence that
CE-Is, ARBs, and statins reduce the rate of ISR,
he anti-inﬂammatory effects of these drugs might
ffect the rate of ISR and TLR after PCI for AMI
atients.
In our study, the long-term outcome of cur-
ently available BMS implantation in AMI patients
anuary
)
Group 1: DES era July
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Table 4 Serial QCA data
Group 2: pre-DES era January
2002—June 2004 (n = 55)
Group 1: DES era July
2004—December 2006 (n = 68)
p
Reference diameter (mm)
Preintervention 2.78± 0.30 2.79± 0.32 0.82
MLD (mm)
Preintervention 0.36± 0.22 0.38± 0.25 0.55
Postintervention
Proximal 2.59± 0.19 2.60± 0.20 0.74
In-stent 2.55± 0.18 2.59± 0.21 0.75
Distal 2.58± 0.22 2.59± 0.24 0.85
Follow-up
Proximal 2.50± 0.19 2.43± 0.30 0.17
In-stent 1.77± 0.66 2.00± 0.43 0.027
Distal 2.29± 0.42 2.39± 0.27 0.11
Diametric stenosis (%)
Preintervention 86.9± 7.7 86.4± 8.7 0.60
Postintervention
Proximal 6.2± 2.3 5.8± 2.6 0.34
In-stent 7.6± 2.2 7.2± 2.5 0.35
Distal 8.0± 2.3 7.5± 2.6 0.41
Follow-up
Proximal 9.6± 3.8 11.9± 9.2 0.085
In-stent 36.9± 23.6 29.2± 14.8 0.028
Distal 18.1± 15.1 13.3± 7.7 0.026
Late loss (mm)
Proximal 0.10± 0.13 0.17± 0.29 0.077
In-stent 0.79± 0.66 0.58± 0.42 0.034
Distal 0.29± 0.41 0.16± 0.26 0.045
Binary restenosis (%)
Proximal 0.0 0.0 —
In-stent 20.0 7.4 0.038
Distal 5.5 1.5 0.22
In-segment 20.0 7.4 0.038
Follow-up length (months) 7.27± 1.51 7.38± 1.50 0.58
Table 5 Comparison of resnosis group and non-restenosis group in Group 1






3.19± 0.41 2.80± 0.45 0.047
Stent length
(mm)
20.8± 4.4 24.4± 4.10 0.083
Lesions that
needed more















was much better than that in stable angina
patients. Several studies have suggested that
the mechanism of in-stent restenosis after BMS
implantation for AMI patients is different from
that for stable angina pectoris patients [20,21].
The pathophysiology of unstable plaques is dif-
ferent from that of the stable atherosclerotic
lesions [22]. The process of neointimal forma-
tion in the stent may also be different between
ACS lesions and stable atherosclerotic lesions.
DES using anti-cancer drugs or immunosuppres-
sant drugs might not be as beneﬁcial for the
treatment of AMI patients as for stable angina
patients.
Although several trials support the safety
of DES implantation for AMI patients [11,12],
there are unsolved problems in DES implan-
tation for AMI patients. The risk of acute,
subacute, and late thrombosis after DES implan-
tation is still controversial. At least, patients
must continue taking antiplatelet agents for much
longer after DES implantation than after BMS
implantation, because of the delay of neoin-
tima formation after DES implantation. It is
often unclear whether AMI patients can take
antiplatelet agents without side effects or hem-
orrhagic complications. Patients must continue to
take antiplatelets after DES implantation much
longer than after BMS implantation. Therefore, we
must be careful to implant DES in the patients
for whom the safety of antiplatelet therapy is
unclear.
In our study, ISR lesions had two characteristics.
First, ISR often occurred after implantation of BMS
with a small diameter because of the small vessel
size. It had been well known that small vessel dis-
ease is a high risk factor of restenosis after stent
implantation. As with small vessel lesions in which
stents with a diameter of more than 2.5mm can-
not be implanted, it may be better to implant DES
to reduce the rate of ISR. Second, many resteno-
sis lesions had needed high-pressure dilatation at
the primary PCI. Sometimes ACS occurs by thrombus
formation in a chronic stenotic lesion. Such lesions
may have bimodal characteristics of ACS and sta-
ble atherosclerosis. As with such ‘acute on chronic’
lesions, DES may be more effective to suppress ISR
than BMS.
Study limitationThis study was a retrospective study with a small
number of patients. A randomized study with a
larger patient population will be necessary to con-
ﬁrm the results.
[H. Fujimoto et al.
onclusions
he primary and long-term outcomes of recent BMS
mplantations in AMI patients is better than those
f previous BMS implantations and may be as good
s those obtained with Cypher stents, unless the
essel diameter is small or the lesion accompanies
evere chronic stenosis. Even in the DES era, BMS
s suitable as the ﬁrst choice for treatment of AMI
atients.
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